The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
Open accessAbstract
Background: Inflammatory bowel disease (IBD) is commonly treated with immunomodulators such as azathioprine and 6-mercaptopurine (6-MP). Studies examining lymphoma risk in IBD patients treated with these medications have been underpowered and have yielded conflicting conclusions. Aims: The purpose of this meta-analysis was to provide a more precise estimate of the relative risk of lymphoma among IBD patients treated with azathioprine or 6-MP. Methods: Studies were included if they were English language, full article, cohort studies specifically designed to evaluate cancer as an adverse outcome of treatment with azathioprine or 6-MP. Pooled standardised incidence ratios were calculated to estimate the relative risk of lymphoma associated with therapy. Heterogeneity was assessed using Poisson regression. Sensitivity analyses examined the influence of individual studies on risk estimate and heterogeneity statistics. Results: Six studies were identified that met our inclusion criteria. When the data were combined across all studies, the pooled relative risk was 4.18 (95% confidence interval 2.07–7.51; 11 observed cases, 2.63 expected). Sensitivity analysis showed that exclusion of any one study had a relatively small effect on the pooled relative risk estimate (range 3.49–5.21) but excluding either the study with the highest or lowest estimated relative risk eliminated the statistically significant heterogeneity. Conclusions: Our data suggest an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine/6-MP. The increased risk of lymphoma could be a result of the medications, the severity of the underlying disease, or a combination of the two.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J. F., Kliewer, E., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z · Cited by 1,165
Statistical methods in cancer research
Gardner, B. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1170 · Cited by 777
Incidence of non-hodgkin lymphoma in kidney and heart transplant recipients
Opelz, G., & Henderson, R. (1993) · The Lancet · doi:10.1016/s0140-6736(05)80084-4 · Cited by 648
Crohn's disease and cancer: A population-based cohort study
Persson, P.-G., Karlén, P., Bernell, O., Leijonmarck, C.-E., Broström, O., Ahlbom, A., & Hellers, G. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90807-9 · Cited by 306
Inflammatory bowel disease is not associated with an increased risk of lymphoma
Lewis, J. D., Bilker, W. B., Brensinger, C., Deren, J. J., Vaughn, D. J., & Strom, B. L. (2001) · Gastroenterology · doi:10.1053/gast.2001.28703 · Cited by 296
Self-citationSilman, A. J., Petrie, J., Hazleman, B., & Evans, S. J. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.12.988 · Cited by 276
Farrell, R. J., Ang, Y., Kileen, P., O'Briain, D. S., Kelleher, D., Keeling, P. W. N., & Weir, D. G. (2000) · Gut · doi:10.1136/gut.47.4.514 · Cited by 260
Inflammatory Bowel Disease Is Not Associated With An Increased Risk Of Lymphoma
&NA; (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200112000-00025 · Cited by 250
Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
Lewis, J. D., Schwartz, J. S., & Lichtenstein, G. R. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70353-2 · Cited by 242
Self-citationExtracolonic malignancies in inflammatory bowel disease
Ekbom, A., Helmick, C., Zack, M., & Adami, H.-O. (1991) · Cancer · doi:10.1002/1097-0142(19910401)67:7<2015::aid-cncr2820670731>3.0.co;2-r · Cited by 226
Increased risk of cancer in ulcerative colitis: a population-based cohort study
Karlén, P. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00067-2 · Cited by 225
Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine
Fraser, A. G., Orchard, T. R., Robinson, E. M., & Jewell, D. P. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01297.x · Cited by 198
Self-citationRisk of lymphoma in inflammatory bowel disease
Loftus, E. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01108-4 · Cited by 173
Hodgkin's disease risk is increased in patients with ulcerative colitis
Palli, D., Trallori, G., Bagnoli, S., Saieva, C., Tarantino, O., Ceroti, M., D'Albasio, G., Pacini, F., Amorosi, A., & Masala, G. (2000) · Gastroenterology · doi:10.1053/gast.2000.16487 · Cited by 138
Malignant Neoplasms Subsequent to Treatment of Inflammatory Bowel Disease With 6-Mercaptopurine
Korelitz, B. I., Mirsky, F. J., Fleisher, M. R., Warman, J. I., Wisch, N., & Gleim, G. W. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01530.x · Cited by 134
Self-citation
Cited by
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Metadata
- Authors
- Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C., & Lewis, J. D.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-07-11
- Volume
- 54
- Issue
- 8
- Pages
- 1121-1125
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2148298419
- Cited by
- 808
- References
- 18
- FWCI
- 24.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.